MAPT and Alzheimer disease: While some studies have reported AD hallmarks such as amyloid or tau pathology in this model (Liu et al., 2020), we could not replicate this using immunofluorescence staining or western blot suggesting that their levels (if present) are below those of most advanced AD models and thus do not represent a major contributor to or proxy of the aging process.